Preconditioning methods influence tumor property in an orthotopic bladder urothelial carcinoma rat model

Miyazaki,Kozo; Morimoto,Yuji; Nishiyama,Nobuhiro; Satoh,Hiroyuki; Tanaka,Masamitsu; Shinomiya,Nariyoshi; Ito,Keiichi

doi:10.3892/mco.2013.214

Preconditioning methods influence tumor property in an orthotopic bladder urothelial carcinoma rat model

Authors:
- Kozo Miyazaki
- Yuji Morimoto
- Nobuhiro Nishiyama
- Hiroyuki Satoh
- Masamitsu Tanaka
- Nariyoshi Shinomiya
- Keiichi Ito
View Affiliations

Affiliations: Division of Clinical Biotechnology, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113‑0033, Japan, Department of Integrative Physiology and Bio‑Nano Medicine, National Defense Medical College, Saitama 359‑8513, Japan, Department of Urology, Tokyo Metropolitan Children's Medical Center, Tokyo 183‑8561, Department of Urology, National Defense Medical College, Saitama 359‑8513, Japan
Published online on: November 15, 2013 https://doi.org/10.3892/mco.2013.214
Pages: 65-70

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Urothelial carcinoma (UC) is an extremely common type of cancer that occurs in the bladder. It has a particularly high rate of recurrence. Therefore, preclinical studies using animal models are essential to determine effective forms of treatment. In the present study, in order to establish an orthotopic bladder UC animal model with clinical relevance, the effects of preconditioning methods on properties of the developed tumor were evaluated. The bladder cavity was pretreated with phosphate‑buffered saline (PBS), acid‑base, trypsin (TRY) or poly (L‑lysine) (PLL) and then rat UC cells (AY‑27) (4x106 cells) were inoculated. The results demonstrated that, two weeks later, the tumorigenic rate (88%) and tumor count (2.3 per rat) were not significantly different among the preconditioning methods, whereas tumor volume and invasion depth into bladder tissue were significantly different. Average tumor volumes were >50 mm3 in the PBS and acid‑base‑treated groups and <10 mm3 in the TRY‑ and PLL‑treated groups. The percentage of invasive tumors (T2 or more advanced stage) was ~75% of total tumors in the PBS‑ and acid‑base‑treated groups, whereas the percentages were reduced in the TRY‑ and PLL‑treated groups (58 and 32%, respectively). Non‑invasive tumors (Ta or T1) accounted for 54% of tumors in the PLL‑treated group, which was 2‑5‑fold higher than the percentages in the remaining groups. Properties of the developed tumor in the rat orthotopic UC model were different depending on preconditioning methods. Therefore, different animal models suitable for a discrete preclinical examination may be established by using the appropriate preconditioning condition.

View Figures

View References

1.	Sylvester RJ, van der Meijden AP, Oosterlinck W, et al: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 49:466–475. 2006. View Article : Google Scholar
2.	Lamm DL: Carcinoma in situ. Urol Clin North Am. 19:499–508. 1992.
3.	Xiao Z, McCallum TJ, Brown KM, et al: Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer. 81:638–646. 1999. View Article : Google Scholar : PubMed/NCBI
4.	Zhou JH, Rosser CJ, Tanaka M, et al: Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Ther. 9:681–686. 2002. View Article : Google Scholar : PubMed/NCBI
5.	Watanabe T, Shinohara N, Sazawa A, et al: An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther. 7:1575–1580. 2000. View Article : Google Scholar
6.	Arentsen HC, Hendricksen K, Oosterwijk E and Witjes JA: Experimental rat bladder urothelial cell carcinoma models. World J Urol. 27:313–317. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Loskog A, Ninalga C, Hedlund T, Alimohammadi M, Malmstrom PU and Totterman TH: Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. Lab Anim. 39:384–393. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Ramesh N, Ge Y, Ennist DL, et al: CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor - armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 12:305–313. 2006. View Article : Google Scholar
9.	Shapiro A, Kelley DR, Oakley DM, Catalona WJ and Ratliff TL: Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guerin. Cancer Res. 44:3051–3054. 1984.
10.	Bisson JF, Parache RM, Droulle P, Notter D, Vigneron C and Guillemin F: A new method of implanting orthotopic rat bladder tumor for experimental therapies. Int J Cancer. 102:280–285. 2002. View Article : Google Scholar : PubMed/NCBI
11.	TNM Classification of Malignant Tumours. 6th edition. (UICC).Hoboken: Wiley-Blackwell; NJ: 2002
12.	Fischer D, Li Y, Ahlemeyer B, Krieglstein J and Kissel T: In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 24:1121–1131. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Arnold LJ Jr, Dagan A, Gutheil J and Kaplan NO: Antineoplastic activity of poly(L-lysine) with some ascites tumor cells. Proc Natl Acad Sci USA. 76:3246–3250. 1979. View Article : Google Scholar : PubMed/NCBI
14.	Reuter M, Schwieger C, Meister A, Karlsson G and Blume A: Poly-l-lysines and poly-l-arginines induce leakage of negatively charged phospholipid vesicles and translocate through the lipid bilayer upon electrostatic binding to the membrane. Biophys Chem. 144:27–37. 2009. View Article : Google Scholar
15.	Yamashita K, Mimori K, Inoue H, Mori M and Sidransky D: A tumor-suppressive role for trypsin in human cancer progression. Cancer Res. 63:6575–6578. 2003.PubMed/NCBI
16.	Patel Y, Rahman S, Siddiqua A, Wilkinson JM, Kakkar VV and Authi KS: Functional characterization of PM6/13, a beta3-specific (GPIIIa/CD61) monoclonal antibody that shows preferential inhibition of fibrinogen binding over fibronectin binding to activated human platelets. Thromb Haemost. 79:177–185. 1998.
17.	Takeichi M: The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development. 102:639–655. 1988.PubMed/NCBI
18.	Hendricksen K, Molkenboer-Kuenen J, Oosterwijk E, Hulsbergen-van de Kaa CA and Witjes JA: Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy. BJU Int. 101:889–893. 2008. View Article : Google Scholar : PubMed/NCBI
19.	El Khatib S, Berrahmoune S, Leroux A, Bezdetnaya L, Guillemin F and D’Hallewin MA: A novel orthotopic bladder tumor model with predictable localization of a solitary tumor. Cancer Biol Ther. 5:1327–1331. 2006.PubMed/NCBI
20.	Pili R, Guo Y, Chang J, Nakanishi H, Martin GR and Passaniti A: Altered angiogenesis underlying age-dependent changes in tumor growth. J Natl Cancer Inst. 86:1303–1314. 1994. View Article : Google Scholar : PubMed/NCBI
21.	Gronlund-Pakkanen S, Wahlfors J, Talja M, et al: The effect of photodynamic therapy on rat urinary bladder with orthotopic urothelial carcinoma. BJU Int. 92:125–130. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Gunther JH, Jurczok A, Wulf T, et al: Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 59:2834–2837. 1999.PubMed/NCBI